435 related articles for article (PubMed ID: 27313785)
1. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.
Trapé AP; Liu S; Cortes AC; Ueno NT; Gonzalez-Angulo AM
J Cancer; 2016; 7(8):947-56. PubMed ID: 27313785
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
3. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
4. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer.
Li Y; Li W; Gong C; Zheng Y; Ouyang Q; Xie N; Qu Q; Ge R; Wang B
Ther Adv Med Oncol; 2021; 13():17588359211022890. PubMed ID: 34178122
[TBL] [Abstract][Full Text] [Related]
5. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
Gao Y; Shen J; Choy E; Mankin H; Hornicek F; Duan Z
Cell Oncol (Dordr); 2017 Jun; 40(3):209-218. PubMed ID: 28243976
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
8. Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence.
Pandey K; Park N; Park KS; Hur J; Cho YB; Kang M; An HJ; Kim S; Hwang S; Moon YW
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260316
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of palbociclib as a breast cancer treatment option: a current update.
Gallanis GT; Pericas RI; Riegel AT; Pohlmann PR
Expert Opin Pharmacother; 2021 Feb; 22(3):281-290. PubMed ID: 33198527
[TBL] [Abstract][Full Text] [Related]
11. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
Abdel-Razeq H; Sharaf B
Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series.
Schettini F; Santo I; Rea CG; Viggiani M; Buono G; Angelis C; Cardalesi C; Lauria R; Giuliano M; Forestieri V; Thomas G; Maione P; Limite G; Accurso A; Malorni L; Placido S; Arpino G
Mol Clin Oncol; 2020 May; 12(5):456-460. PubMed ID: 32257203
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
14. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer.
Finn RS; Liu Y; Zhu Z; Martin M; Rugo HS; Diéras V; Im SA; Gelmon KA; Harbeck N; Lu DR; Gauthier E; Huang Bartlett C; Slamon DJ
Clin Cancer Res; 2020 Jan; 26(1):110-121. PubMed ID: 31527167
[TBL] [Abstract][Full Text] [Related]
15. Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
Katuwal NB; Kang MS; Ghosh M; Hong SD; Jeong YG; Park SM; Kim SG; Sohn J; Kim TH; Moon YW
J Exp Clin Cancer Res; 2023 Nov; 42(1):325. PubMed ID: 38017459
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
17. Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.
Pandey K; Katuwal NB; Park N; Hur J; Cho YB; Kim SK; Lee SA; Kim I; Lee SR; Moon YW
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008374
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
20. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]